Clinical Trials Logo

Colorectal Neoplasms clinical trials

View clinical trials related to Colorectal Neoplasms.

Filter by:

NCT ID: NCT05639413 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

COBRAF
Start date: January 2023
Phase: N/A
Study type: Interventional

The study will be conducted in patients with metastatic colorectal cancer (mCRC) harboring a BRAFV600E mutation, to collect clinical data and biological samples to be used for research but also to gather real-world clinical data concerning the treatments and the survival outcomes in patients with this pathology.

NCT ID: NCT05638243 Recruiting - Colorectal Cancer Clinical Trials

Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program

METHOD-3
Start date: August 20, 2022
Phase:
Study type: Observational

The incidence rate and mortality of colorectal cancer are increasing year by year. Most colorectal cancer develops from colorectal adenoma and is a disease that can be prevented and controlled. Thanks to early screening, the incidence rate and mortality of colorectal cancer have declined year by year. However, due to poor compliance with colonoscopy and the lack of efficient and convenient early screening methods, it is difficult to screen for colorectal cancer in China. According to the data from Shanghai Xuhui District Center for Disease Control and Prevention, the proportion of colonoscopies in high-risk groups for colorectal cancer is less than 18%. This project plans to use the latest colorectal cancer screening technology, namely, 5hmC detection in peripheral blood and DNA methylation detection in feces, for those who are positive in the colorectal cancer incidence risk questionnaire or fecal occult blood in Xuhui District, Shanghai. It is strongly recommended that subjects with positive screening should undergo colonoscopy, to effectively improve the rate of colonoscopy and the early diagnosis rate of colorectal cancer. At the same time, to explore the screening efficiency of the early diagnosis model of 5hmC cancer.

NCT ID: NCT05636085 Not yet recruiting - Colorectal Cancer Clinical Trials

Clinical Performance of the Mainz Biomed Colorectal Cancer Screening Test for Colorectal Cancer and Advanced Adenoma

reconAAsense
Start date: June 1, 2023
Phase:
Study type: Observational

This study is to determine how the Mainz Biomed Colorectal Cancer Screening Test works when used in people aged ≥45 years of age and at an average risk of developing colorectal cancer.

NCT ID: NCT05635630 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Predictive Value of ctDNA for NED Status in mCRC and Its Utility in Guiding Therapeutic Intervention

Start date: June 24, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to detect the prognostic value of longitudinal monitoring circulating tumor DNA (ctDNA) for no evidence of disease (NED) status in metastatic colorectal cancer (mCRC) patients and its utility in guiding therapeutic intervention. The main questions it aims to answer are: 1. Whether ctDNA monitoring could evaluate NED status ahead of normal radiologic monitoring. What about the concordance of evaluating NED status by ctDNA monitoring compared with normal radiologic monitoring? 2. Whether the patients with ctDNA positive status could benefit from early therapeutic intervention. Patients who receive any kinds of therapies with the aim of NED and are confirmed by clinical and radiologic examination will go through longitudinal ctDNA monitoring. According to the results of ctDNA monitoring, the patients will be divided into ctDNA positive group and ctDNA negative group. Patients in ctDNA positive group will receive individual therapeutic plan decided by the investigator. Patients in ctDNA negative group will receive regular examinations. When radiologic recurrences are confirmed, the patients will be re-evaluated for a second opportunity of radical resection.

NCT ID: NCT05635149 Recruiting - Clinical trials for Colorectal Adenocarcinoma

Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer

Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

This study was an observational cohort study to investigate the efficacy predictors of fuquinitinib combined with anti-PD-1 monoclonal antibody for third-line treatment and above in Chinese patients with advanced colorectal cancer.

NCT ID: NCT05634590 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

Start date: December 2022
Phase: Phase 2
Study type: Interventional

RAS mutations are found in nearly half of colorectal cancer patients. However, there is no targeted driver gene drugs have been approved for RAS-mutated patients. For RAS mutant metastatic colorectal cancer, the commonly used treatment regimen is bevacizumab combined with chemotherapy.

NCT ID: NCT05632744 Not yet recruiting - Colorectal Cancer Clinical Trials

Safety and Performance of CG-100 Intraluminal Bypass Device (Modified Version) in Colorectal and Coloanal Anastomoses

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The investigational device in the study is a modified version of the approved CG-100 device which has the same intended use but will be assessed as part of this study in a sub-population of subjects with colon lumen diameter ranging from 25 mm to 32 mm with anastomosis creation within 10 cm from the anal verge.

NCT ID: NCT05631873 Recruiting - Colorectal Cancer Clinical Trials

Colonoscopy Screening: Setting Epic Follow-up Times

ColoSET
Start date: November 18, 2022
Phase: N/A
Study type: Interventional

Screening for colorectal cancer can reduce its incidence and mortality but is a complex, error-prone process. The value of screening with colonoscopy is in removing pre-cancerous polyps that increase one's risk for future cancer. Abnormal results are common, and failure to receive recommended follow-up undermines the benefits of screening, violates the trust that patients place in their providers, and increases medicolegal risk. This proposal seeks to ensure that the foundation of safety systems, the recommendations for the follow-up interval reflect current guideline recommendations and are accurately updated. Specifically, the investigators will implement and evaluate in a randomized trial a new colonoscopy result letter as part of usual care that automatically updates the recommended follow-up interval in the patient's health record compared to the current result letter format.

NCT ID: NCT05631574 Not yet recruiting - Colorectal Cancer Clinical Trials

Study of BMF-219 in Adult Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer.

Start date: December 2022
Phase: Phase 1
Study type: Interventional

A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort 2), and CRC (Cohort 3).

NCT ID: NCT05631041 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

Effect of Silymarin in Metastatic Colorectal Cancer Patients

Start date: November 2022
Phase: Phase 3
Study type: Interventional

this work is aim to assess the antitumor effect of silymarin in patients with metastatic colorectal cancer receiving chemotherapy with or without target therapy (Bevacizumab).